Retacrit(R) Data Confirm Equivalent Efficacy To Epoetin Alfa In Renal Anaemia

Hospira (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today presented new data showing Retacrit® (epoetin zeta) corrects low haemoglobin (Hb) levels as effectively and rapidly as epoetin alfa (Erypo®) in patients with chronic kidney disease (CKD).

More: continued here

Filed under: Blood on September 8th, 2008